Literature DB >> 15795597

Hepatocyte glycogen accumulation in patients undergoing dietary management of urea cycle defects mimics storage disease.

L Miles1, J E Heubi, Kevin E Bove.   

Abstract

OBJECTIVES: Anecdotal reports have described excess hepatocyte glycogen in patients with urea cycle enzyme defects. Retrospectively, the authors evaluated the prevalence and possible cause of liver glycogen accumulation in such patients.
METHODS: The authors searched the files of the Division of Pathology at Cincinnati Children's Hospital from 1975 and 2004 for cases of urea cycle enzyme defects and identified 11 patients who had had liver biopsy performed and/or liver transplantation. All patients were on diets containing essential amino acids as the protein source before liver biopsy and/or transplantation.
RESULTS: All but one patient had focal or diffuse glycogen accumulation in hepatocytes in at least one specimen by light microscopic examination. Two young infants also had cholestasis. Electron microscopy performed on six patients showed diffuse or focal glycogen excess in the cytoplasm of individual hepatocytes. Biochemical studies of three patients revealed two with hepatic glycogen content in the upper normal range and one that was abnormally high. Glycolytic enzyme activities were normal in two patients, and one patient had low phosphorylase activity.
CONCLUSIONS: Hepatocyte glycogen accumulation in urea cycle enzyme defects resembles that seen in glycogen storage disease but can be distinguished in most cases by non-uniformity of distribution and/or the absence of sinusoidal compression by expanded hepatocytes. We speculate that therapeutic modification of dietary protein content by restriction to essential amino acids, including leucine, may promote glycogen accumulation by increasing insulin secretion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15795597     DOI: 10.1097/01.mpg.0000157200.33486.ce

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  4 in total

1.  Variable X-chromosome inactivation and enlargement of pericentral glutamine synthetase zones in the liver of heterozygous females with OTC deficiency.

Authors:  Dita Musalkova; Eva Sticova; Martin Reboun; Jitka Sokolova; Jakub Krijt; Jitka Honzikova; Jiri Gurka; Magdalena Neroldova; Tomas Honzik; Jiri Zeman; Milan Jirsa; Lenka Dvorakova; Martin Hrebicek
Journal:  Virchows Arch       Date:  2018-04-06       Impact factor: 4.064

2.  Chronic liver disease and impaired hepatic glycogen metabolism in argininosuccinate lyase deficiency.

Authors:  Lindsay C Burrage; Simran Madan; Xiaohui Li; Saima Ali; Mahmoud Mohammad; Bridget M Stroup; Ming-Ming Jiang; Racel Cela; Terry Bertin; Zixue Jin; Jian Dai; Danielle Guffey; Milton Finegold; Sandesh Nagamani; Charles G Minard; Juan Marini; Prakash Masand; Deborah Schady; Benjamin L Shneider; Daniel H Leung; Deeksha Bali; Brendan Lee
Journal:  JCI Insight       Date:  2020-02-27

3.  Treatment and outcomes of dogs with hepatocutaneous syndrome or hepatocutaneous-associated hepatopathy.

Authors:  John P Loftus; Adam J Miller; Sharon A Center; Jeanine Peters-Kennedy; Michael Astor
Journal:  J Vet Intern Med       Date:  2021-11-25       Impact factor: 3.333

4.  Hepatocellular Adenoma in a Patient with Ornithine Transcarbamylase Deficiency.

Authors:  Lin Cheng; Yajuan Liu; Wenjing Wang; J L Merritt; Matthew Yeh
Journal:  Case Reports Hepatol       Date:  2019-10-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.